The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Real-world Overall Survival Using Oncology Electronic Health Record Data: Friends of Cancer Research Pilot》. Authors are Lasiter, Laura; Tymejczyk, Olga; Garrett-Mayer, Elizabeth; Baxi, Shrujal; Belli, Andrew J.; Boyd, Marley; Christian, Jennifer B.; Cohen, Aaron B.; Espirito, Janet L.; Hansen, Eric; Sweetnam, Connor; Robert, Nicholas J.; Small, Mackenzie; Stewart, Mark D.; Izano, Monika A.; Wagner, Joseph; Natanzon, Yanina; Rivera, Donna R.; Allen, Jeff.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). Through the article, more information about this compound (cas:41575-94-4) is conveyed.
In prior work, Friends of Cancer Research convened multiple data partners to establish standardized definitions for oncol. real-world end points derived from electronic health records (EHRs) and claims data. Here, we assessed the performance of real-world overall survival (rwOS) from data sets sourced from EHRs by evaluating the ability of the end point to reflect expected differences from a previous randomized controlled trial across five data sources, after applying inclusion/exclusion criteria. The KEYNOTE-189 clin. trial protocol of platinum doublet chemotherapy (chemotherapy) vs. programmed cell death protein 1 (PD-1) in combination with platinum doublet chemotherapy (PD-1 combination) in first-line nonsquamous metastatic non-small cell lung cancer guided retrospective cohort selection. The Kaplan-Meier product limit estimator was used to calculate 12-mo rwOS with 95% confidence intervals (CIs) in each data source. Cox proportional hazards models estimated hazard ratios (HRs) and associated 95% CIs, controlled for prognostic factors. Once the inclusion/exclusion criteria were applied, the five resulting data sets included 155 to 1,501 patients in the chemotherapy cohort and 36 to 405 patients in the PD-1 combination cohort. Twelve-month rwOS ranged from 45% to 58% in the chemotherapy cohort and 44% to 68% in the PD-1 combination cohort. The adjusted HR for death ranged from 0.80 (95% CI: 0.69, 0.93) to 1.15 (95% CI: 0.71, 1.85), controlling for age, gender, performance status, and smoking status. This study yielded insights regarding data capture, including ability of real-world data to precisely identify patient populations and the impact of criteria on end points. Sensitivity analyses could elucidate data set-specific factors that drive results.
I hope my short article helps more people learn about this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II))Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). Apart from the compound(41575-94-4), you can read my other articles to know other related compounds.
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics